132 related articles for article (PubMed ID: 12883033)
1. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Huss WJ; Barrios RJ; Greenberg NM
Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
3. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.
da Silva RF; Banzato TP; Alves LF; Carvalho JE; Agarwal R; Cagnon VHA
Cell Tissue Res; 2020 Feb; 379(2):407-420. PubMed ID: 31473819
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
6. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
8. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
[TBL] [Abstract][Full Text] [Related]
9. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
10. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
11. Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion.
Ogawara K; Abe S; Un K; Yoshizawa Y; Kimura T; Higaki K
J Pharm Sci; 2014 Aug; 103(8):2464-9. PubMed ID: 24985750
[TBL] [Abstract][Full Text] [Related]
12. SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.
Peloquin GL; Johnston L; Damarla M; Damico RL; Hassoun PM; Kolb TM
Respir Res; 2019 Jun; 20(1):123. PubMed ID: 31208454
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
Ellis LM; Takahashi Y; Liu W; Shaheen RM
Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Itokawa T; Nokihara H; Nishioka Y; Sone S; Iwamoto Y; Yamada Y; Cherrington J; McMahon G; Shibuya M; Kuwano M; Ono M
Mol Cancer Ther; 2002 Mar; 1(5):295-302. PubMed ID: 12489845
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
Keskin U; Totan Y; Karadağ R; Erdurmuş M; Aydın B
Ophthalmic Res; 2012; 47(1):13-8. PubMed ID: 21691137
[TBL] [Abstract][Full Text] [Related]
16. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
Davis DW; Takamori R; Raut CP; Xiong HQ; Herbst RS; Stadler WM; Heymach JV; Demetri GD; Rashid A; Shen Y; Wen S; Abbruzzese JL; McConkey DJ
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):678-89. PubMed ID: 15701856
[TBL] [Abstract][Full Text] [Related]
18. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
19. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
